| Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy CL Gay, RJ Bosch, J Ritz, JM Hataye, E Aga, RL Tressler, SW Mason, ... The Journal of infectious diseases 215 (11), 1725-1733, 2017 | 231 | 2017 |
| The lncRNA SLNCR1 mediates melanoma invasion through a conserved SRA1-like region K Schmidt, CE Joyce, F Buquicchio, A Brown, J Ritz, RJ Distel, CH Yoon, ... Cell reports 15 (9), 2025-2037, 2016 | 113 | 2016 |
| The lncRNA SLNCR recruits the androgen receptor to EGR1-bound genes in melanoma and inhibits expression of tumor suppressor p21 K Schmidt, JS Carroll, E Yee, DD Thomas, L Wert-Lamas, SC Neier, ... Cell reports 27 (8), 2493-2507. e4, 2019 | 67 | 2019 |
| Evaluating our ability to predict the structural disruption of RNA by SNPs J Ritz, JS Martin, A Laederach BMC genomics 13 (Suppl 4), S6, 2012 | 60 | 2012 |
| Evolutionary evidence for alternative structure in RNA sequence co-variation J Ritz, JS Martin, A Laederach PLoS computational biology 9 (7), e1003152, 2013 | 51 | 2013 |
| Structural effects of linkage disequilibrium on the transcriptome JS Martin, M Halvorsen, L Davis-Neulander, J Ritz, C Gopinath, ... Rna 18 (1), 77-87, 2012 | 51 | 2012 |
| Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 KW Chew, C Moser, ES Daar, DA Wohl, JZ Li, RW Coombs, J Ritz, ... Nature communications 13 (1), 4931, 2022 | 39 | 2022 |
| Sharing and archiving nucleic acid structure mapping data P Rocca-Serra, S Bellaousov, A Birmingham, C Chen, P Cordero, R Das, ... Rna 17 (7), 1204-1212, 2011 | 36 | 2011 |
| Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial R Gross, J Ritz, MD Hughes, R Salata, P Mugyenyi, E Hogg, L Wieclaw, ... The Lancet Digital Health 1 (1), e26-e34, 2019 | 33 | 2019 |
| Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study B Grinsztejn, MD Hughes, J Ritz, R Salata, P Mugyenyi, E Hogg, ... The lancet HIV 6 (9), e588-e600, 2019 | 30 | 2019 |
| Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART SA Riddler, L Zheng, CM Durand, J Ritz, RA Koup, J Ledgerwood, ... Open Forum Infectious Diseases 5 (10), ofy242, 2018 | 27 | 2018 |
| Symptom and viral rebound in untreated SARS-CoV-2 infection R Deo, MC Choudhary, C Moser, J Ritz, ES Daar, DA Wohl, AL Greninger, ... Annals of internal medicine 176 (3), 348-354, 2023 | 22 | 2023 |
| Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial MC Choudhary, KW Chew, R Deo, JP Flynn, J Regan, CR Crain, C Moser, ... Nature microbiology 7 (11), 1906-1917, 2022 | 22 | 2022 |
| Viral and symptom rebound in untreated COVID-19 infection R Deo, MC Choudhary, C Moser, J Ritz, ES Daar, DA Wohl, AL Greninger, ... medRxiv, 2022 | 17 | 2022 |
| HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized, controlled trial KT Tashima, LM Smeaton, CJ Fichtenbaum, A Andrade, JJ Eron, ... Annals of internal medicine 163 (12), 908-917, 2015 | 17 | 2015 |
| Emergence of SARS-CoV-2 resistance with monoclonal antibody therapy MC Choudhary, KW Chew, R Deo, JP Flynn, J Regan, CR Crain, C Moser, ... medRxiv, 2021.09. 03.21263105, 2021 | 16 | 2021 |
| Recurrence of symptoms following a 2-day symptom free period in patients with COVID-19 DM Smith, JZ Li, C Moser, E Yeh, JS Currier, KW Chew, MD Hughes, ... JAMA Network Open 5 (10), e2238867-e2238867, 2022 | 15 | 2022 |
| Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS) RT Gandhi, KT Tashima, LM Smeaton, V Vu, J Ritz, A Andrade, JJ Eron, ... The Journal of Infectious Diseases 221 (9), 1407-1415, 2020 | 15 | 2020 |
| Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection J Boucau, KW Chew, MC Choudhary, R Deo, J Regan, JP Flynn, ... Cell Reports Medicine 3 (7), 2022 | 13 | 2022 |
| Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies amubarvimab plus romlusevimab in nonhospitalized patients with COVID-19 TH Evering, KW Chew, MJ Giganti, C Moser, M Pinilla, DA Wohl, ... Annals of internal medicine 176 (5), 658-666, 2023 | 12 | 2023 |
